GAMMA Investing LLC Purchases New Holdings in DexCom, Inc. (NASDAQ:DXCM)

GAMMA Investing LLC purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,678 shares of the medical device company’s stock, valued at approximately $325,000.

Other large investors also recently bought and sold shares of the company. Winslow Capital Management LLC bought a new stake in DexCom during the 3rd quarter valued at about $173,120,000. Vaughan Nelson Investment Management L.P. increased its stake in DexCom by 16,943.0% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 1,459,730 shares of the medical device company’s stock valued at $136,193,000 after purchasing an additional 1,451,165 shares in the last quarter. Westfield Capital Management Co. LP grew its stake in shares of DexCom by 79.3% in the third quarter. Westfield Capital Management Co. LP now owns 1,847,865 shares of the medical device company’s stock worth $172,406,000 after acquiring an additional 817,351 shares during the period. TimesSquare Capital Management LLC grew its stake in shares of DexCom by 11,359.1% in the third quarter. TimesSquare Capital Management LLC now owns 733,380 shares of the medical device company’s stock worth $68,424,000 after acquiring an additional 726,980 shares during the period. Finally, Sands Capital Management LLC grew its stake in shares of DexCom by 4.3% in the third quarter. Sands Capital Management LLC now owns 13,660,670 shares of the medical device company’s stock worth $1,274,541,000 after acquiring an additional 557,543 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DXCM has been the subject of a number of research analyst reports. Royal Bank of Canada initiated coverage on shares of DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Citigroup boosted their target price on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Tuesday. UBS Group boosted their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Finally, Raymond James boosted their target price on shares of DexCom from $147.00 to $151.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $141.40.

DexCom Trading Up 2.9 %

DXCM stock opened at $137.87 on Thursday. The company has a quick ratio of 2.48, a current ratio of 2.84 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a twelve month low of $74.75 and a twelve month high of $142.00. The stock has a market capitalization of $54.60 billion, a price-to-earnings ratio of 105.25, a price-to-earnings-growth ratio of 2.30 and a beta of 1.20. The firm’s fifty day simple moving average is $130.58 and its two-hundred day simple moving average is $117.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.07. DexCom had a net margin of 14.95% and a return on equity of 28.31%. The firm had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the prior year, the business posted $0.34 earnings per share. The business’s revenue for the quarter was up 26.9% on a year-over-year basis. As a group, analysts anticipate that DexCom, Inc. will post 1.76 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Kevin R. Sayer sold 81,007 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other DexCom news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at $10,747,722.01. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $133.36, for a total transaction of $10,803,093.52. Following the sale, the chief executive officer now directly owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. Insiders sold a total of 189,375 shares of company stock valued at $25,530,859 over the last three months. 0.41% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.